rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.47360/1995-4484-2021-31-36rsp-2987Research ArticleПРОБЛЕМЫ РЕВМАТОЛОГИИ В ПЕРИОД ПАНДЕМИИ КОРОНОВИРУСНОЙ БОЛЕЗНИ 2019PROBLEMS OF RHEUMATOLOGY DURING THE 2019 CORONAVIRUS PANDEMICCOVID-19 и ревматология: год спустяCOVID-19 and rheumatology: A year laterhttps://orcid.org/0000-0001-7091-2054БеловБ. С.BelovB. S.

Белов Борис Сергеевич

115522, Москва, Каширское шоссе, 34а

Boris Belov

115522, Moscow, Kashirskoye Highway, 34A

belovbor@yandex.ruhttps://orcid.org/0000-0002-6068-3080ЛилаА. М.LilaA. M.

115522, Москва, Каширское шоссе, 34а

125993, г. Москва, ул. Баррикадная, 2/1, стр. 1

Aleksander M. Lila, 

115522, Moscow, Kashirskoye Highway, 34A

125993, Moscow, Barricadnaya str., 2/1, p. 1

ФГБНУ Научно-исследовательский институт ревматологии им В.А. НасоновойРоссияVA Nasonova Research Institute of RheumatologyRussian FederationФГБНУ Научно-исследовательский институт ревматологии им В.А. Насоновой; ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования», кафедра ревматологииРоссияVA Nasonova Research Institute of Rheumatology; Russian Medical Academy of Postgraduate Education, Department of RheumatologyRussian Federation2021020320215913136Copyright © Белов Б.С., Лила А.М., 20212021Белов Б.С., Лила А.М.Belov B.S., Lila A.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/2987

В течение последнего года накоплено огромное количество данных по различным аспектам коронавирусной болезни 2019 (coronavirus disease, COVID-19), связанной с вирусом SARS-CoV-2 (severe acute respiratory syndrome coronavirus-2). При этом чрезвычайно важно выявление взаимосвязей между COVID-19 и иммуновоспалительными ревматическими заболеваниями (ИВРЗ). Показано, что частота развития COVID-19 у пациентов с ревматическими заболеваниями значимо не отличается от таковой в популяции. Риск тяжелого течения и неблагоприятных исходов у пациентов с ИВРЗ, как и в популяции, значимо связан с возрастом и сопутствующими заболеваниями и не ассоциируется с исходным применением большинства антиревматических препаратов. Накопление знаний о патогенезе COVID-19 создало предпосылки для репозиционирования противоревматических лекарственных препаратов с целью их применения для лечения пациентов с указанной инфекцией. В современных условиях пандемии коронавирусной инфекции большие надежды связаны с созданием и быстрейшим внедрением в клиническую практику различных вакцин против COVID-19. Однако эффективность, иммуногенность и безопасность этих вакцин у больных ИВРЗ в обязательном порядке должны быть изучены в ходе контролируемых исследований. В целом в наших знаниях сохраняется достаточное количество пробелов, касающихся ревматологических аспектов такой многогранной проблемы, как COVID-19.

An enormous body of evidence on various aspects of the coronavirus disease 2019, COVID-19 associated with the SARS-CoV-2 virus (severe acute respiratory syndrome coronavirus-2) has been accumulated over the past year. Meanwhile, investigated relationship between COVID-19 and rheumatic immune-mediated inflammatory diseases (IMIDs) and certain identified similarities were of paramount importance. It was shown that the incidence of COVID-19 in patients with rheumatic diseases does not significantly differ from that in general population. The risk of severe course and unfavorable COVID-19 outcomes in patients with rheumatic IMIDs is significantly associated with older age and comorbidities – as in general population, and is not aggravated by preceding use of the majority of antirheumatic drugs. Gaining better insights into pathogenesis of COVID-19 provided sound prerequisites for anti-rheumatic drugs repurposing and substantiated their use for treatment of COVID-19 infection. Under current COVID-19 pandemic circumstances, accelerated development and invention of various COVID-19 vaccines offers a great hope to curb the tide of pandemic. However, the efficacy, immunogenicity, and safety of these vaccines in patients with rheumatic IMIDs must be studied in controlled clinical trials. Generally speaking, there are still numerous blind spots in our knowledge of rheumatological aspects of such a versatile and polymorphous condition as COVID-19 infection.

COVID-19иммуновоспалительные ревматические заболеванияглюкокортикоидыгидроксихлорохинтоцилизумаббарицитинибвакцинацияCOVID-19rheumatic immune-mediated inflammatory diseasesglucocorticoidshydroxychloroquinetocilizumabbaricitibvaccinationИсследование не имело спонсорской поддержки.ReferencesНасонов ЕЛ. Коронавирусная болезнь 2019 (COVID-19): размышления ревматолога. Научно-практическая ревматология. 2020;58(2):123–132. doi: 10.14412/1995-4484-2020-123-132Nasonov EL. Coronavirus disease 2019 (COVID-19): a rheumatologist’s thoughts. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2020;58(2):123–132 (In Russ.). doi: 10.14412/1995-4484-2020-123-132Kingsmore KM, Grammer AC, Lipsky PE. Drug repurposing to improve treatment of rheumatic autoimmune inflammatory diseases. Nat Rev Rheumatol. 2020;16(1):32–52. doi: 10.1038/s41584-019-0337-0Kingsmore KM, Grammer AC, Lipsky PE. Drug repurposing to improve treatment of rheumatic autoimmune inflammatory diseases. Nat Rev Rheumatol. 2020;16(1):32–52. doi: 10.1038/s41584-019-0337-0Sarzi-Puttini P, Marotto D, Caporali R, et al. Prevalence of COVID infections in a population of rheumatic patients from Lombardy and Marche treated with biological drugs or small molecules: A multicentre retrospective study. J Autoimmun. 2021;116:102545. doi: 10.1016/j.jaut.2020.102545Sarzi-Puttini P, Marotto D, Caporali R, et al. Prevalence of COVID infections in a population of rheumatic patients from Lombardy and Marche treated with biological drugs or small molecules: A multicentre retrospective study. J Autoimmun. 2021;116:102545. doi: 10.1016/j.jaut.2020.102545Emmi G, Bettiol A, Mattioli I, et al. SARS-CoV-2 infection among patients with systemic autoimmune diseases. Autoimmun Rev. 2020;19(7): 102575. doi: 10.1016/j.autrev.2020.102575Emmi G, Bettiol A, Mattioli I, et al. SARS-CoV-2 infection among patients with systemic autoimmune diseases. Autoimmun Rev. 2020;19(7): 102575. doi: 10.1016/j.autrev.2020.102575Costantino F, Bahier L, Tarancón LC, et al. COVID-19 in French patients with chronic inflammatory rheumatic diseases: clinical features, risk factors and treatment adherence. Joint Bone Spine. 2020:105095. doi: 10.1016/j.jbspin.2020.105095Costantino F, Bahier L, Tarancón LC, et al. COVID-19 in French patients with chronic inflammatory rheumatic diseases: clinical features, risk factors and treatment adherence. Joint Bone Spine. 2020:105095. doi: 10.1016/j.jbspin.2020.105095Pablos JL, Abasolo L, Alvaro-Gracia JM, et al. Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases. Ann Rheum Dis. 2020; 79:1170–3. doi: 10.1101/2020.05.11.20097808Pablos JL, Abasolo L, Alvaro-Gracia JM, et al. Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases. Ann Rheum Dis. 2020; 79:1170–3. doi: 10.1101/2020.05.11.20097808Gianfrancesco M, Hyrich KL, Al-Adely S, et al. Characteristics associated with hospitalization for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020;79(7):859–866. doi: 10.1136/annrheumdis-2020-217871Gianfrancesco M, Hyrich KL, Al-Adely S, et al. Characteristics associated with hospitalization for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020;79(7):859–866. doi: 10.1136/annrheumdis-2020-217871FAI2R /SFR/SNFMI/SOFREMIP/CRI/IMIDIATE consortium and contributors. Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients. Ann Rheum Dis. 2020 Dec 2: annrheumdis-2020-218–310. doi: 10.1136/annrheumdis-2020-218-310FAI2R /SFR/SNFMI/SOFREMIP/CRI/IMIDIATE consortium and contributors. Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients. Ann Rheum Dis. 2020 Dec 2: annrheumdis-2020-218–310. doi: 10.1136/annrheumdis-2020-218-310Serling-Boyd N, D’Silva KM, Hsu TY, et al. Coronavirus disease 2019 outcomes among patients with rheumatic diseases 6 months into the pandemic. Ann Rheum Dis. 2020 Nov 30: annrheumdis-2020-219–279. doi: 10.1136/annrheumdis-2020-219-279Serling-Boyd N, D’Silva KM, Hsu TY, et al. Coronavirus disease 2019 outcomes among patients with rheumatic diseases 6 months into the pandemic. Ann Rheum Dis. 2020 Nov 30: annrheumdis-2020-219–279. doi: 10.1136/annrheumdis-2020-219-279Ahmed S, Gasparyan AY, Zimba O. Comorbidities in rheumatic diseases need special consideration during the COVID-19 pandemic. Rheumatol Int. 2021; 1–14. doi: 10.1007/s00296-020-04764-5Ahmed S, Gasparyan AY, Zimba O. Comorbidities in rheumatic diseases need special consideration during the COVID-19 pandemic. Rheumatol Int. 2021; 1–14. doi: 10.1007/s00296-020-04764-5Tomelleri A, Sartorelli S, Campochiaro C, et al. Impact of COVID-19 pandemic on patients with large-vessel vasculitis in Italy: a monocentric survey. Ann Rheum Dis. 2020;79(9):1252–1253. doi: 10.1136/annrheumdis-2020-217600Tomelleri A, Sartorelli S, Campochiaro C, et al. Impact of COVID-19 pandemic on patients with large-vessel vasculitis in Italy: a monocentric survey. Ann Rheum Dis. 2020;79(9):1252–1253. doi: 10.1136/annrheumdis-2020-217600Loarce-Martos J, García-Fernández A, López-Gutiérrez F, et al. High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study. Rheumatol Int. 2020;40(12):2015–2021. doi: 10.1007/s00296-020-04699-xLoarce-Martos J, García-Fernández A, López-Gutiérrez F, et al. High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study. Rheumatol Int. 2020;40(12):2015–2021. doi: 10.1007/s00296-020-04699-xKow CS, Hasan SS. Use of rituximab and the risk of adverse clinical outcomes in COVID-19 patients with systemic rheumatic disease. Rheumatol Int. 2020;40(12):2117–2118. doi: 10.1007/s00296-020-04715-0Kow CS, Hasan SS. Use of rituximab and the risk of adverse clinical outcomes in COVID-19 patients with systemic rheumatic disease. Rheumatol Int. 2020;40(12):2117–2118. doi: 10.1007/s00296-020-04715-0Насонов ЕЛ, Бекетова ТВ, Решетняк ТМ, и др. Коронавирусная болезнь 2019 (COVID-19) и иммуновоспалительные ревматические заболевания: на перекрестке проблем тромбовоспаления и аутоиммунитета. Научно-практическая ревматология. 2020;58(4):353–367. doi: 10.47360/1995-4484-2020-353-367Nasonov EL, Beketova TV, Reshetnyak TM, et al. Coronavirus disease 2019 (COVID-19) and immune-mediated (autoimmune) inflammatory rheumatic diseases: at the crossroads of thromboinflammation and autoimmunity. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2020;58(4):353– 367 (in Russ.) doi: 10.47360/1995-4484-2020-353-367Loo J, Spittle DA, Newnham M. COVID-19, immunothrombosis and venous thromboembolism: biological mechanisms. Thorax. 2021 Jan 6: thoraxjnl-2020-216243. doi: 10.1136/thoraxjnl-2020-216243Loo J, Spittle DA, Newnham M. COVID-19, immunothrombosis and venous thromboembolism: biological mechanisms. Thorax. 2021 Jan 6: thoraxjnl-2020-216243. doi: 10.1136/thoraxjnl-2020-216243Solomon DH, Bucala R, Kaplan MJ, Nigrovic PA. The “Infodemic” of COVID-19. Arthritis Rheumatol. 2020;72(11): 1806–1808. doi: 10.1002/art.41468Solomon DH, Bucala R, Kaplan MJ, Nigrovic PA. The “Infodemic” of COVID-19. Arthritis Rheumatol. 2020;72(11): 1806–1808. doi: 10.1002/art.41468Sinha N, Balayla G. Hydroxychloroquine and COVID-19. Postgrad Med J. 2020;96(1139):550-555. doi: 10.1136/postgradmedj-2020-137785Sinha N, Balayla G. Hydroxychloroquine and COVID-19. Postgrad Med J. 2020;96(1139):550-555. doi: 10.1136/postgradmedj-2020-137785Mikuls TR, Johnson SR, Fraenkel L, et al. American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 3. Arthritis Rheumatol. 2020 Dec 5. doi: 10.1002/art.41596Mikuls TR, Johnson SR, Fraenkel L, et al. American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 3. Arthritis Rheumatol. 2020 Dec 5. doi: 10.1002/art.41596RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, et al. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. N Engl J Med. 2020 Jul 17:NEJMoa2021436. doi: 10.1056/NEJMoa2021436RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, et al. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. N Engl J Med. 2020 Jul 17:NEJMoa2021436. doi: 10.1056/NEJMoa2021436Зайцев АА, Голухова ЕЗ, Мамалыга МЛ, и др. Эффективность пульс терапии метилпреднизолоном у пациентов с COVID-19. Клиническая микробио логия и антимикробная химиотерапия. 2020; 22(2):88-91. doi: 10.36488/cmac.2020.2.88- 91Zaitsev A.A.1, Golukhova E.Z., Mamalyga M.L et al. Efficacy of methylprednisolone pulse therapy in patients with COVID-19. Klinicheskaya mikrobiologiya i antimikrobnaya khimioterapiya = Clinical Microbiology and Antimicrobial Chemotherapy. 2020;22(2):88–91 (In Russ.). doi: 10.36488/cmac.2020.2.88- 91van Paassen J, Vos JS, Hoekstra EM, et al. Corticosteroid use in COVID-19 patients: a systematic review and meta-analysis on clinical outcomes. Crit Care. 2020;24(1):696. doi: 10.1186/s13054-020-03400-9van Paassen J, Vos JS, Hoekstra EM, et al. Corticosteroid use in COVID-19 patients: a systematic review and meta-analysis on clinical outcomes. Crit Care. 2020;24(1):696. doi: 10.1186/s13054-020-03400-9Matthay MA, Wick KD. Corticosteroids, COVID-19 pneumonia, and acute respiratory distress syndrome. J Clin Invest. 2020;130(12):6218–6221. doi: 10.1172/JCI143331Matthay MA, Wick KD. Corticosteroids, COVID-19 pneumonia, and acute respiratory distress syndrome. J Clin Invest. 2020;130(12):6218–6221. doi: 10.1172/JCI143331Rosas I, Bräu N, Water M, et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia. medRxiv. 2020. doi: 10.1101/ 2020.08.27.20183442Rosas I, Bräu N, Water M, et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia. medRxiv. 2020. doi: 10.1101/ 2020.08.27.20183442Salvarani C, Dolci G, Massari M, et al. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial. JAMA Intern Med. 2020. doi: 10.1001/jamainternmed.2020.6615Salvarani C, Dolci G, Massari M, et al. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial. JAMA Intern Med. 2020. doi: 10.1001/jamainternmed.2020.6615Hermine O, Xavier M, Tharaux P, et al. CORIMUNO-19 Collaborative Group Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial. JAMA Intern Med. 2020. doi: 10.1001/jamainternmed.2020.6820Hermine O, Xavier M, Tharaux P, et al. CORIMUNO-19 Collaborative Group Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial. JAMA Intern Med. 2020. doi: 10.1001/jamainternmed.2020.6820Stone JH, Frigault M, Serling-Boyd N, et al. BACC Bay Tocilizumab Trial Investigators Efficacy of tocilizumab in patients hospitalized with COVID-19. New Engl J Med. 2020. doi: 10.1056/NEJMoa2028836Stone JH, Frigault M, Serling-Boyd N, et al. BACC Bay Tocilizumab Trial Investigators Efficacy of tocilizumab in patients hospitalized with COVID-19. New Engl J Med. 2020. doi: 10.1056/NEJMoa2028836Tleyjeh IM, Kashour Z, Damlaj M, et al. Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis. Clin Microbiol Infect. 2020; S1198-743X(20)30690-X. doi: 10.1016/j.cmi.2020.10.036Tleyjeh IM, Kashour Z, Damlaj M, et al. Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis. Clin Microbiol Infect. 2020; S1198-743X(20)30690-X. doi: 10.1016/j.cmi.2020.10.036Salama C, Han J, Yau L, et al. Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia. N Engl J Med. 2021;384(1):20–30. doi: 10.1056/NEJMoa2030340Salama C, Han J, Yau L, et al. Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia. N Engl J Med. 2021;384(1):20–30. doi: 10.1056/NEJMoa2030340Моисеев СВ, Авдеев СН, Тао ЕА, и др. Эффективность тоцилизумаба у пациентов с COVID-19, госпитализированных в ОРИТ: ретроспективное когортное исследование. Клин.фармакол. тер. 2020;29(4):17-25. doi: 10.32756/0869-5490-2020-4-17-25Moiseev S, Avdeev S, Tao E, et al. Efficacy of tocilizumab in the intensive care unit patients with COVID-19: a retrospective cohort study. Klinicheskaya farmakologiya i terapiya = Clin Pharmacol Ther. 2020;29(4):17–25 (In Russ.). doi: 10.32756/0869-5490-2020-4-17-25Narain S, Stefanov DG, Chau AS, et al. Northwell COVID-19 Research Consortium. Comparative Survival Analysis of Immunomodulatory Therapy for Coronavirus Disease 2019 Cytokine Storm. Chest. 2020;S0012-3692(20)34901-1. doi: 10.1016/j.chest.2020.09.275Narain S, Stefanov DG, Chau AS, et al. Northwell COVID-19 Research Consortium. Comparative Survival Analysis of Immunomodulatory Therapy for Coronavirus Disease 2019 Cytokine Storm. Chest. 2020;S0012-3692(20)34901-1. doi: 10.1016/j.chest.2020.09.275Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. N Engl J Med. 2020; NEJMoa2031994. doi: 10.1056/NEJMoa2031994Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. N Engl J Med. 2020; NEJMoa2031994. doi: 10.1056/NEJMoa2031994Coronavirus (COVID-19) Update: FDA Authorizes Drug Combination for Treatment of COVID-19. Доступно по ссылке: https://www.fda.gov/news-events/press-announcements/coronavi-rus-covid-19-update-fda-authorizes-drug-combination-treatment-covid-19?utm_medium=email&utm_source=govdeliveryCoronavirus (COVID-19) Update: FDA Authorizes Drug Combination for Treatment of COVID-19. Доступно по ссылке: https://www.fda.gov/news-events/press-announcements/coronavi-rus-covid-19-update-fda-authorizes-drug-combination-treatment-covid-19?utm_medium=email&utm_source=govdelivery

The authors declare that there are no conflicts of interest present.